Baxter (BAX) Reports Q3 Earnings: What Key Metrics Have to Say

Core Insights - Baxter International reported a revenue of $2.7 billion for the quarter ended September 2024, reflecting a 27.2% decrease year-over-year and a significant miss of 29.72% against the Zacks Consensus Estimate of $3.84 billion [1] - The earnings per share (EPS) for the quarter was $0.80, which is an increase from $0.68 in the same quarter last year, resulting in an EPS surprise of +2.56% compared to the consensus estimate of $0.78 [1] Revenue Performance - Net Sales in Pharmaceuticals (U.S.) were $178 million, below the average estimate of $210.04 million, marking an 8.7% decline year-over-year [3] - International Pharmaceuticals Net Sales reached $410 million, slightly below the average estimate of $417.62 million, with a year-over-year increase of 6.5% [3] - Net Sales in Advanced Surgery were $272 million, exceeding the average estimate of $266.68 million, with a year-over-year growth of 6.7% [3] - Infusion Therapies and Technologies Net Sales were $1.07 billion, slightly above the average estimate of $1.06 billion [3] - Overall, several segments underperformed against analyst estimates, while some showed modest growth year-over-year [3] Stock Performance - Baxter's shares have declined by 2.7% over the past month, contrasting with a 4.9% increase in the Zacks S&P 500 composite [4] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [4]